KRAS

  •   George Lundberg, MD

    On May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.

    .

  •  

    How an Expert Would Treat His Own Advanced Lung Cancer

    With: Jack West, MD

    A new cancer diagnosis is overwhelming. Patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks lung cancer expert Howard (Jack) West, MD, how he would handle his own diagnosis of advanced lung cancer. Dr. West is a Princeton- and Harvard-educated oncologist with additional training and experience in Boston and Seattle focusing on lung cancer.… Read more »

  •   George Lundberg, MD

    Article from the academic journal Oncology, curated by Contributing Editor George Lundberg, MD, who notes:

    Molecular testing is essential to guide effective treatment in metastatic colorectal cancer. This academic review article provides a good overview of the topic.

    .

  •  

    Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer Patients

    Lola Rahib, PhD

    In collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for pancreatic cancer patients at a conference in San Diego, CA, today. The “Special Conference on Advancing Precision Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies” is hosted by the… Read more »

  •  

    Cancer Commons and xCures Invite Participation from Patients Who Try New Combo Therapy for Pancreatic Cancer

    Treatment for metastatic pancreatic cancer has seen progress in recent years, but outcomes remain poor and treatment advances that can prolong patients’ lives, even for a few months, are eagerly awaited. Two papers published today in the scientific journal Nature Medicine report that a new combination of two drugs that are FDA-approved for other conditions may significantly delay progression of pancreatic cancer in cells… Read more »

  •  

    The Trouble With KRAS

    Emma Shtivelman, PhD

    Mutations in the gene that encodes the KRAS protein are frequently encountered in various human cancers. They are found in about 30% of non-small cell lung cancers (NSCLCs), making KRAS the single most common gene mutated in this cancer. The rate of KRAS mutations in other cancers, such as pancreatic or colorectal, is even higher. A mutant KRAS protein that is always in the… Read more »